Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Page standards status: Informative |
<Evidence xmlns="http://hl7.org/fhir">
<id value="236987"/>
<meta>
<versionId value="72"/>
<lastUpdated value="2026-08-06T17:15:59.259Z"/>
<profile
value="http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"/>
</meta>
<language value="en"/>
<text>
<status value="extensions"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: Evidence 236987</b></p><a name="236987"> </a><a name="hc236987"> </a><div style="display: inline-block; background-color: #fbffeb; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">version: 72; Last updated: 2026-08-06 17:15:59+0000</p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-comparative-evidence.html">ComparativeEvidence</a></p></div><p><b>ArtifactPublicationStatus</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-status-type active}">Active</span></p><p><b>url</b>: <a href="Evidence-236987.html">Evidence MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes</a></p><p><b>identifier</b>: FEvIR Object Identifier/236987, outcomeId/109588, picoId/85798, sectionId/73215, <a href="http://terminology.hl7.org/7.5.0/NamingSystem-uri.html" title="As defined by RFC 3986 (http://www.ietf.org/rfc/rfc3986.txt)(with many schemes defined in many RFCs). For OIDs and UUIDs, use the URN form (urn:oid:(note: lowercase) and urn:uuid:). See http://www.ietf.org/rfc/rfc3001.txt and http://www.ietf.org/rfc/rfc4122.txt
This oid is used as an identifier II.root to indicate the the extension is an absolute URI (technically, an IRI). Typically, this is used for OIDs and GUIDs. Note that when this OID is used with OIDs and GUIDs, the II.extension should start with urn:oid or urn:uuid:
Note that this OID is created to aid with interconversion between CDA and FHIR - FHIR uses urn:ietf:rfc:3986 as equivalent to this OID. URIs as identifiers appear more commonly in FHIR.
This OID may also be used in CD.codeSystem.">Uniform Resource Identifier (URI)</a>/urn:oid:2.16.840.1.113883.4.642.40.44.22.150</p><p><b>version</b>: 1.0.0-ballot3</p><p><b>name</b>: Body_weight_from_MAGICapp_109588</p><p><b>title</b>: MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes</p><p><b>citeAs</b>: </p><div><p>MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236987. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/236987. Computable resource at: https://fevir.net/resources/Evidence/236987#json.</p>
</div><p><b>status</b>: Active</p><p><b>date</b>: 2026-11-05 14:34:28+0000</p><p><b>author</b>: Computable Publishing®: MAGIC-to-FEvIR Converter: </p><p><b>publisher</b>: HL7 International / Clinical Decision Support</p><p><b>contact</b>: HL7 International / Clinical Decision Support: <a href="http://www.hl7.org/Special/committees/dss">http://www.hl7.org/Special/committees/dss</a></p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="CodeSystem-179423.html#179423-evidence-communication">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 ComparativeEvidence}">ComparativeEvidence</span></td></tr></table><p><b>copyright</b>: </p><div><p>Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse).</p>
</div><h3>RelatesTos</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Target[x]</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/artifact-relationship-type part-of}">Part Of</span></td><td>MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)</td></tr></table><p><b>description</b>: </p><div><p>This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>
</div><p><b>assertion</b>: </p><div><p>SGLT2 inhibitors probably reduce body weight compared with GLP-1 receptor agonists.</p>
</div><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Adults with type 2 diabetes</p>
</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href="Group-236947.html">Adults with type 2 diabetes and CVD and CKD</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA</p>
</div><p><b>variableRole</b>: Exposure</p><p><b>comparatorCategory</b>: GLP-1 RA</p><p><b>observed</b>: <a href="EvidenceVariable-236950.html">GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Body weight</p>
</div><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href="EvidenceVariable-236986.html">Body weight</a></p></blockquote><p><b>synthesisType</b>: <span title="Codes:">SYSTEMATIC_REVIEW</span></p><p><b>studyDesign</b>: <span title="Codes:">NOTSET</span></p><blockquote><p><b>statistic</b></p><p><b>description</b>: </p><div><p>MD -0.47 Kg (CI95 -0.09 Kg to -0.85 Kg)</p>
</div><p><b>statisticType</b>: <span title="Codes:{https://fevir.net/sevco STATO:0000457}">difference in means</span></p><p><b>quantity</b>: -0.47 Kg</p><h3>SampleSizes</h3><table class="grid"><tr><td style="display: none">-</td><td><b>NumberOfStudies</b></td><td><b>NumberOfParticipants</b></td></tr><tr><td style="display: none">*</td><td>2</td><td>1139</td></tr></table><h3>AttributeEstimates</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Range</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">CI95</span></td><td>-0.09--0.85 Kg</td></tr></table></blockquote><blockquote><p><b>certainty</b></p><p><b>description</b>: </p><div><p>Due to serious inconsistency</p>
</div><p><b>type</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/certainty-type Overall}">Overall certainty</span></p><p><b>rating</b>: <span title="Codes:{https://fevir.net/resources/CodeSystem/27834 RJCS-2004}">Moderate certainty</span></p><h3>Subcomponents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Rating</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">Risk of Bias</span></td><td><span title="Codes:">NOTSET</span></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">Inconsistency</span></td><td><span title="Codes:">SERIOUS</span></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">Indirectness</span></td><td><span title="Codes:">NOTSET</span></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">Imprecision</span></td><td><span title="Codes:">NOTSET</span></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">Publication Bias</span></td><td><span title="Codes:">NOTSET</span></td></tr></table></blockquote></div>
</text>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status">
<valueCodeableConcept>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/cited-artifact-status-type"/>
<code value="active"/>
<display value="Active"/>
</coding>
</valueCodeableConcept>
</extension>
<url value="https://fevir.net/resources/Evidence/236987"/>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="ACSN"/>
<display value="Accession ID"/>
</coding>
<text value="FEvIR Object Identifier"/>
</type>
<system value="https://fevir.net/FOI"/>
<value value="236987"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<identifier>
<type>
<text value="outcomeId"/>
</type>
<system value="https://app.magicapp.org/#/guidelines"/>
<value value="109588"/>
</identifier>
<identifier>
<type>
<text value="picoId"/>
</type>
<system value="https://app.magicapp.org/#/guidelines"/>
<value value="85798"/>
</identifier>
<identifier>
<type>
<text value="sectionId"/>
</type>
<system value="https://app.magicapp.org/#/guidelines"/>
<value value="73215"/>
</identifier>
<identifier>
<system value="urn:ietf:rfc:3986"/>
<value value="urn:oid:2.16.840.1.113883.4.642.40.44.22.150"/>
</identifier>
<version value="1.0.0-ballot3"/>
<name value="Body_weight_from_MAGICapp_109588"/>
<title
value="MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
<citeAs
value="MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236987. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/236987. Computable resource at: https://fevir.net/resources/Evidence/236987#json."/>
<status value="active"/>
<date value="2026-11-05T14:34:28+00:00"/>
<author>
<name value="Computable Publishing®: MAGIC-to-FEvIR Converter"/>
</author>
<publisher value="HL7 International / Clinical Decision Support"/>
<contact>
<name value="HL7 International / Clinical Decision Support"/>
<telecom>
<system value="url"/>
<value value="http://www.hl7.org/Special/committees/dss"/>
</telecom>
</contact>
<useContext>
<code>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="evidence-communication"/>
<display value="Evidence Communication"/>
</code>
<valueCodeableConcept>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="ComparativeEvidence"/>
<display value="ComparativeEvidence"/>
</coding>
</valueCodeableConcept>
</useContext>
<copyright
value="Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse)."/>
<relatesTo>
<type>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/artifact-relationship-type"/>
<code value="part-of"/>
<display value="Part Of"/>
</coding>
</type>
<targetReference>
<type value="Composition"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-conversion-report"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"/>
</targetReference>
</relatesTo>
<description
value="This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide."/>
<assertion
value="SGLT2 inhibitors probably reduce body weight compared with GLP-1 receptor agonists."/>
<variableDefinition>
<description value="Adults with type 2 diabetes"/>
<variableRole value="population"/>
<observed>🔗
<reference value="Group/236947"/>
<type value="Group"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-population-group-85394-85798"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="Adults with type 2 diabetes and CVD and CKD"/>
</observed>
</variableDefinition>
<variableDefinition>
<description value="GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA"/>
<variableRole value="exposure"/>
<comparatorCategory value="GLP-1 RA"/>
<observed>🔗
<reference value="EvidenceVariable/236950"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-group-assignment-85394-85798"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA"/>
</observed>
</variableDefinition>
<variableDefinition>
<description value="Body weight"/>
<variableRole value="outcome"/>
<observed>🔗
<reference value="EvidenceVariable/236986"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-109588"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="Body weight"/>
</observed>
</variableDefinition>
<synthesisType>
<text value="SYSTEMATIC_REVIEW"/>
</synthesisType>
<studyDesign>
<text value="NOTSET"/>
</studyDesign>
<statistic>
<description value="MD -0.47 Kg (CI95 -0.09 Kg to -0.85 Kg)"/>
<statisticType>
<coding>
<system value="https://fevir.net/sevco"/>
<code value="STATO:0000457"/>
<display value="difference in means"/>
</coding>
</statisticType>
<quantity>
<value value="-0.47"/>
<unit value="Kg"/>
</quantity>
<sampleSize>
<numberOfStudies value="2"/>
<numberOfParticipants value="1139"/>
</sampleSize>
<attributeEstimate>
<type>
<text value="CI95"/>
</type>
<range>
<low>
<value value="-0.09"/>
<unit value="Kg"/>
</low>
<high>
<value value="-0.85"/>
<unit value="Kg"/>
</high>
</range>
</attributeEstimate>
</statistic>
<certainty>
<description value="Due to serious inconsistency"/>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/certainty-type"/>
<code value="Overall"/>
<display value="Overall certainty"/>
</coding>
</type>
<rating>
<coding>
<system value="https://fevir.net/resources/CodeSystem/27834"/>
<code value="RJCS-2004"/>
<display value="Moderate certainty"/>
</coding>
</rating>
<subcomponent>
<type>
<text value="Risk of Bias"/>
</type>
<rating>
<text value="NOTSET"/>
</rating>
</subcomponent>
<subcomponent>
<type>
<text value="Inconsistency"/>
</type>
<rating>
<text value="SERIOUS"/>
</rating>
</subcomponent>
<subcomponent>
<type>
<text value="Indirectness"/>
</type>
<rating>
<text value="NOTSET"/>
</rating>
</subcomponent>
<subcomponent>
<type>
<text value="Imprecision"/>
</type>
<rating>
<text value="NOTSET"/>
</rating>
</subcomponent>
<subcomponent>
<type>
<text value="Publication Bias"/>
</type>
<rating>
<text value="NOTSET"/>
</rating>
</subcomponent>
</certainty>
</Evidence>